Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral HealthcareGlobeNewsWire • 01/04/24
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023GlobeNewsWire • 01/03/24
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product ClassificationGlobeNewsWire • 10/18/23
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of DirectorsGlobeNewsWire • 09/07/23
Celularity Announces Multi-Year Research Collaboration Services Agreement With RegeneronGlobeNewsWire • 08/29/23
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic ApplicationsGlobeNewsWire • 07/27/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celularity Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 07/19/23
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in StudiesGlobeNewsWire • 07/18/23
Celularity Announces Presentation at Upcoming 7th International Conference on OrthopedicsGlobeNewsWire • 06/29/23
Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing CapabilityGlobeNewsWire • 06/01/23
CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTSPRNewsWire • 05/23/23
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity's Halal-Certified Biomaterial ProductsGlobeNewsWire • 05/23/23
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn's Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula FormationGlobeNewsWire • 05/19/23
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial ProductsGlobeNewsWire • 05/10/23
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell TherapyGlobeNewsWire • 05/01/23
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid LeukemiaGlobeNewsWire • 04/27/23
Celularity's Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”GlobeNewsWire • 04/12/23
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual MeetingGlobeNewsWire • 04/04/23
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity's Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA's Center For Devices And Radiological HealthGlobeNewsWire • 04/03/23